Tweet
Hi! I'm Jackie. I am currently studying Cancer Biology and hope to better my understanding and my knowledge about sequence analysis!
-
-
Welcome
Welcome to the forum, Jackie. Here is a recent open access article I thought I would mention in case you may be interested:
Title:
Methods, Challenges, and Promise of Next-Generation Sequencing in Cancer Biology
PMCID:
PMC3238319 -
Hello. I am Huimin, also new to the forum.
Thanks Joann for your suggestion.
A quick question. For RNAseq 50 bp HiSeq2000, v3 chemistry, can I ran 6 samples per lane with single end? or paired end maybe to double the # of reads? My purpose is to get the differential expression between two groups, each group 3 replicates so total 6 samples.
Thanks for your comments!Comment
-
Hi
Hi hug2001,
Welcome. For the best exposure of your technical questions to obtain a rapid response here, please be sure to post them by searching/choosing a more specific forum, such as the Illumina forum.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment